Another Regeneron Bear is Born
October 20, 2017 at 15:57 PM EDT
Shares of Regeneron are falling today after an analyst at Barclays warned that expectations surrounding the eczema drug Dupixent are too high. Here's why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|